Skip to main content
. 2017 Sep 26;9(4):40. doi: 10.3390/pharmaceutics9040040

Table 2.

Hepatic microsome activities for cyp2b (bupropion), cyp2c (tolbutamide and repaglinide), cyp2d (bufuralol), cyp2e (chlorzoxazone), cyp2j (ebastine), cyp3a (midazolam) and cyp4a (dodecanoic acid) in C57BL6 mice fed a normal diet (ND) or a HFD (LDR, low-diet responders; and HDR, high-diet responders after an eight-week period).

Liver ND LDR HDR
(nmol/mg protein/min)
Bupropion Hydroxybupropion 0.030 ± 0.004 0.030 ± 0.004 0.023 ± 0.002 **
Tolbutamide Hydroxytolbutamide 0.22 ± 0.01 0.15 ± 0.01 0.17 ± 0.02
Repaglinide M1-repaglinide 0.050 ± 0.006 0.007 ± 0.002 0.0081 ± 0.0003
Repaglinide Hydroxyrepaglinide 0.0020 ± 0.0001 0.0010 ± 0.0002 0.0013 ± 0.0004 **
Bufuralol Hydroxybufuralol 0.26 ± 0.05 0.19 ± 0.06 0.21 ± 0.06
Chlorzoxazone Hydroxychlorzoxazone 2.0 ± 0.1 2.4 ± 0.3 ** 1.9 ± 0.1
Ebastine Hydroxyebastine and carebastine 0.044 ± 0.007 0.07 ± 0.01 0.057 ± 0.008 *
Midazolam 1′-hydroxymidazolam 0.32 ± 0.06 0.06 ± 0.01 0.06 ± 0.01
Dodecanoic acid 12-hydroxydecanoic acid 0.19 ± 0.03 0.27 ± 0.05 0.3 ± 0.1 *

Cyp450 activities are reported as the rate of metabolite formation in nmol/mg protein/min ± SD (* p < 0.05, ** p < 0.01, p < 0.001 compared to ND).